With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

På Altinget tror vi på politik – og på, at politik og politisk debat gør en forskel. Derfor udvider vi vores debatunivers med ...

Field hospitals in Thai refugee camps, landmine clearance in war zones, and drugs to treat millions suffering from diseases ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

The Danish Embassy in Thailand, under the leadership of H.E. Mr. Danny Annan, Ambassador of Denmark to Thailand and Cambodia ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo ligger efter fredagens kurstab på 4,34 pct. et mulehår fra at miste førerpositionen som Europas mest værdifulde selskab. Mærsk-aktien led under fald i fragtrater. Ørsted-aktien blev sendt i ...

Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban on TikTok, and Qorvo stock jumps after activist Starboard Value amasses a ...

Novo Nordisk har tredoblet dosen af det aktive stof semaglutid i nyt studie, der viser et højere vægttab Forsøgspersoner har opnået et højere vægttab med en større dosis af Novo Nordisk ...

The leaders of major Danish companies, including the CEO of Ozempic-maker Novo Nordisk, have met with the Danish Prime Minister after being summoned to discuss the country’s ongoing spat with ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.